Eosinophilia-myalgia syndrome (EMS) is a multisystemic disease that occurs in patients who have consumed products containing l-tryptophan. Prominent features include incapacitating myalgias, arthralgias, neuropathies, and eosinophilia. Despite the frequent association of dysphagia, dyspnea, and the potential for aspiration, the otolaryngology literature is devoid of information on EMS. In order to determine the frequency of otolaryngic symptoms, questionnaires were distributed to patients with EMS in 33 different US states. Among the 28 various head and neck manifestations studied, 70% of EMS patients complained of generalized muscle spasms, 66% xerostomia, 62% dyspnea, and 56% dysphagia. In addition, the epidemiology, clinical presentation, diagnostic criteria, and treatment options are discussed. This paper assesses the frequency of otolaryngic manifestations of EMS, as well as introduces this syndrome to the otolaryngologist—head and neck surgeon. It is important for the otolaryngologist to be aware of EMS and its manifestations and treatments so that patients with this potentially lethal disease can receive appropriate evaluation and expeditious treatment.
HertzmanPABlevinsWLMayerJGreenfieldBTingMGleichGJ. Association of the eosinophilia-myalgia syndrome with the ingestion of l-tryptophan. N Engl J Med1990;13: 864–73.
2.
Martinez-OsunaPWallachPMSeleznickMJ. Treatment of eosinophilia-myalgia syndrome. Semin Arthritis Rheum1991;21: 110–21.
Centers for Disease Control. Eosinophilia-myalgia syndrome and the l-tryptophan containing products—New Mexico, Minnesota, Oregon, New York. MMWR1989;38: 785–8.
5.
VargaJUittoJJimenezSA. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med1992;116: 140–7.
6.
VargaJJimenezSAUittoJ. l-Tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis. J Invest Dermatol1993;100: 97S–105S.
7.
RoufsJB. Review of l-tryptophan and eosinophilia-myalgia syndrome. J Am Diet Assoc1992;92: 844–50.
8.
GrovesRWSimpsonKJKoblarSPitzalisCHayRJ. Tryptophan induced eosinophilia-myalgia syndrome: clinical and microscopic findings. J R Soc Med1992;85: 111–2.
9.
KaufmanLD. The eosinophilia-myalgia syndrome: current concepts and future directions. Clin Exp Rheumatol1992;10: 87–91.
10.
SwygertLAMaesEFSewellLEMillerLFalkHKilbourneEM. Eosinophilia-myalgia syndrome: results of national surveillance. JAMA1990;264: 1698–703.
HedbergKUrbachDSlutskerLMatsonPFlemingD. Eosinophilia-myalgia syndrome: natural history in a populationbased cohort. Arch Intern Med1992;152: 1889–92.
13.
PatmasMA. Eosinophilia-myalgia syndrome not associated with l-tryptophan. NJ Med1992;89: 285–6.
14.
KambMLMurphyJJJonesJL. Eosinophilia-myalgia syndrome in l-tryptophan-exposed patients. JAMA1992;267: 77–82.
15.
MartinRWDuffyJEngelAG. The clinical spectrum of the eosinophilia-myalgia syndrome associated with l-tryptophan ingestion. Ann Intern Med1990;113: 124–34.
16.
SilverRMHeyesMPMaizeJCQuearryBVionnet-FuassetMSternbergEM. Scleroderma, fasciitis with eosinophilia associated with the ingestion of tryptophan. N Engl J Med1990;322: 874–81.
17.
KaufmanLDSeidmanRJGruberBL. l-Tryptophan associated eosinophilia perimyositis, neuritis and fasciitis. Medicine (Baltimore)1990;69: 187–99.
18.
Heiman-PattersonTDBirdSJParryGJ. Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann Neurol1990;28: 522–8.
19.
KruppLBMasurDMKaufmanLD. Neurocognitive dysfunction in the eosinophilia-myalgia syndrome. Neurology1993;43: 931–6.
20.
ReadCAClauwDWeirCDa SilvaA TaveiraKatzP. Dyspnea and pulmonary function in the l-tryptophan associated eosinophilia-myalgia syndrome. Chest1992;101: 1282–6.
21.
HertzmanPAMaddouxGLSternbergEM. Repeated coronary artery spasm in a young woman with the eosinophilic myalgia syndrome. JAMA1992;267: 2932–4.
22.
SackKECriswellLA. Eosinophilia-myalgia syndrome: the aftermath. South Med J1992;85: 878–82.
23.
VargaJHeiman-PattersonTDEmeryDL. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum1990;19: 313–28.
FreundlichBWerthVPRookAH. l-Tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med1990;112: 758–62.
26.
LinJDPhelpsRGGordonML. Pathologic manifestations of the eosinophilia-myalgia syndrome. Hum Pathol1992;23: 429–37.
27.
SmithSARoelofsRIGertnerE. Microangiopathy in the eosinophilia myalgia syndrome. J Rheumatol1990;17: 1544–50.
28.
KilbourneEMSwygertLAPhilenRM. Interim guidance on the eosinophilia-myalgia syndrome. Ann Intern Med1990;112: 85–6.
29.
FeldmanSRSilverRMMaizeJC. A histopathologic comparison of Shulman's syndrome (diffuse fasciitis with eosinophils) and the fasciitis associated with the eosinophilia-myalgia syndrome. J Am Acad Dermatol1992;26: 95–100.
30.
HertzmanPAFalkHKilbourneEMPageSShulmanLE. The eosinophilia-myalgia syndrome: The Los Alamos Conference. J Rheumatol1991;18: 867–73.
31.
VargaJGrifinRNewmanJHJimenezSA. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with l-tryptophan use. J Rheumatol1991;18: 259–63.
32.
HenningKJJean-BaptisteESinghTHillRHFriedmanSM. Eosinophilia-myalgia syndrome in patients ingesting a single source of l-tryptophan. J Rheumatol1993;20: 273–8.
33.
Centers for Disease Control. Analysis of l-tryptophan for the etiology of eosinophilia-myalgia syndrome. MMWR1990;39: 589–91.
34.
BelongiaEAHedbergCWGleichGJ. An investigation of the cause of eosinophilic-myalgia syndrome associated with tryptophan use. N Engl J Med1990;323: 357–65.
35.
CroffordLJRaderJIDalakasMC. l-Tryptophan implicated in human eosinophilia myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest1990;86: 1757–63.
36.
AdachiJNaitoTUenoYOgawaYNinomiyaITatsunoY. Metabolism and distribution in the rat of peak E substance, a constituent in l-tryptophan product implicated in eosinophilia-myalgia syndrome. Arch Toxicol1993;67: 284–9.
37.
NightingaleSL. Update on EMS and l-tryptophan. JAMA1992;268: 1828.
38.
SilverRMSutherlandSECarreiraPHeyesMP. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. J Rheumatol1992;19: 69–73.
39.
DrazninERosenbergNL. Intensive rehabilitation approach to eosinophilia myalgia syndrome associated with severe polyneuropathy. Arch Phys Med Rehabil1993;74: 774–6.
40.
Centers for Disease Control. Eosinophilia-myalgia syndrome — New Mexico. MMWR JAMA1989;262: 3116.
41.
CulpepperRCWilliamsRGMeasePJKoepsellTDKobayashiJM. Natural history of the eosinophilia-myalgia syndrome. Ann Intern Med1991;115: 437–42.
42.
NolfoEWright-BrowneVTherrienMArdolinoAMacinskiZ. Plasmapheresis in a case of eosinophilia-myalgia syndrome with ascending polyneuropathy. Chest1991;100: 584.
